Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Codiak BioSciences, Inc is a biotechnology business based in the US. Codiak BioSciences shares (CDAK.US) are listed on the NASDAQ and all prices are listed in US Dollars. Codiak BioSciences employs 101 staff and has a trailing 12-month revenue of around $1.4 million.
|Latest market close||$N/A|
|52-week range||$7.9 - $37.85|
|50-day moving average||$23.2183|
|200-day moving average||$16.3378|
|Wall St. target price||$35|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||N/A|
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
|Revenue TTM||USD$1.4 million|
|Gross profit TTM||USD$-59,113,000|
|Return on assets TTM||0%|
|Return on equity TTM||0%|
|Market capitalisation||USD$499.2 million|
TTM: trailing 12 months
There are currently 701,693 Codiak BioSciences shares held short by investors – that's known as Codiak BioSciences's "short interest". This figure is 20.8% up from 581,092 last month.
There are a few different ways that this level of interest in shorting Codiak BioSciences shares can be evaluated.
Codiak BioSciences's "short interest ratio" (SIR) is the quantity of Codiak BioSciences shares currently shorted divided by the average quantity of Codiak BioSciences shares traded daily (recently around 407961.04651163). Codiak BioSciences's SIR currently stands at 1.72. In other words for every 100,000 Codiak BioSciences shares traded daily on the market, roughly 1720 shares are currently held short.
However Codiak BioSciences's short interest can also be evaluated against the total number of Codiak BioSciences shares, or, against the total number of tradable Codiak BioSciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Codiak BioSciences's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Codiak BioSciences shares in existence, roughly 40 shares are currently held short) or 0.0733% of the tradable shares (for every 100,000 tradable Codiak BioSciences shares, roughly 73 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Codiak BioSciences.
Find out more about how you can short Codiak BioSciences stock.
We're not expecting Codiak BioSciences to pay a dividend over the next 12 months. However, you can browse other dividend-paying shares in our guide.
Codiak BioSciences, Inc. is harnessing exosomes?natural intercellular messengers?to pioneer a new class of biologic medicines, exosome therapeutics. It develops the engEx Platform, versatile exosome engineering and manufacturing platform, to expand upon the innate properties of exosomes to design novel exosome therapeutics. The company's two lead engEx product candidates, exoSTING and exoIL-12. Its engEx Platform has the potential to produce a broad pipeline of product candidates for the treatment of diseases with high unmet medical need, including in the areas of oncology, immune-based diseases, metabolic and fibrotic disorders, neurodegenerative disorders, and rare diseases. Codiak BioSciences, Inc. has a strategic collaboration with the Ragon Institute of MGH, MIT and Harvard to investigate the potential of exoVACC vaccine platform for SARS-CoV-2 and human immunodeficiency virus. The company was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Steps to owning and managing 17 Education & Technology Group stocks, with 24-hour and historical pricing before you buy.
Steps to owning and managing StealthGas stocks, with 24-hour and historical pricing before you buy.
Steps to owning and managing Enterprise Products stocks, with 24-hour and historical pricing before you buy.
Steps to owning and managing DXC stocks, with 24-hour and historical pricing before you buy.
Steps to owning and managing Bionano Genomics stocks, with 24-hour and historical pricing before you buy.
Steps to owning and managing Sunrun stocks, with 24-hour and historical pricing before you buy.
Steps to owning and managing PLDT stocks, with 24-hour and historical pricing before you buy.
Steps to owning and managing Oxford Lane Capital stocks, with 24-hour and historical pricing before you buy.
Steps to owning and managing NetEase stocks, with 24-hour and historical pricing before you buy.
Steps to owning and managing Gulfport Energy stocks, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.